Eurofins Viracor: All Resources

We recognize the significant challenges posed by infectious diseases and the critical need for accurate diagnostics. With over 40 years of experience, we are committed to innovation, continuously advancing our testing capabilities to empower healthcare providers. Our portfolio includes cutting-edge assays such as Next-Generation Sequencing panels, multiplex PCR, and comprehensive serological tests, all designed to deliver rapid and precise diagnostic information. We also emphasize collaboration with academic institutions and industry partners to drive breakthroughs in infectious disease testing. Our dedication to research and development enables us to provide reliable solutions that enhance patient management and public health interventions. Through our innovative testing strategies, we strive to improve patient outcomes and support effective healthcare practices.

In 2005, Randy Moritz was diagnosed with polycystic kidney disease. Fifteen years later, doctors told him he needed a transplant and removed both his kidneys. His wife, Karen, was a match and the surgery was booked for March 2020... But then COVID-19 hit.

For Hematology/Oncology patients the ExPeCT^TM anti-CD19 (FMC63) CAR T assay provides interventional data which may provide information on the expansion and persistence of the genetically modified T-cells used as therapeutic treatment for specific lymphomas and leukemias (Chimeric Antigen Receptor T-cell therapy or CAR T). Eurofins Viracor has developed and validated a multiplexed quantitative real-time PCR (qPCR) assay targeting FMC63 for the longitudinal monitoring of CD19-directed CAR T-cell therapy.

The National CMV Foundation, Leading Physicians cCMV Testing Advocates, and Eurofins Viracor will help you learn more about congenital cytomegalovirus (cCMV) and how early testing with non-invasive sample types (like saliva) can lead to improved outcomes. This succinct and informative webinar will discuss the impact testing can make for neonates at risk, types of testing, and the advocacy work you can get involved with (not only in June, but year round). The great panel also answers viewer's questions after the main presentation.

Over the past two decades, cellular immune response to cytomegalovirus (CMV) and other viral pathogens has been an interesting area of research and has now evolved into a clinical application of assays that provide a precise measure of cellular response. Current antiviral preventative strategies have shown improved efficacy, but CMV continues to be one of the more common clinically significant infections in solid organ transplant (SOT) recipients, hematopoietic stem cell transplant (HSCT) recipients, and other immunocompromising conditions like HIV.

This bi-lateral lung transplant recipient is a 65 year-old male patient who received his lung transplant due to end-stage lung disease secondary to non-CF bronchiectasis. The donor and recipient CMV serostatus is D+/R+. The patient’s initial peri-operative course was complicated by difficult explant, primary graft dysfunction, respiratory failure requiring prolonged mechanical ventilation, renal insufficiency and recurrent infectious concerns, including pseudomonas and stenotrophomonas pneumonias.

These knowledgeable physicians share how they manage their solid organ transplant patients at risk for CMV by utilizing CMV inSIGHT™ T Cell immunity. These unique case studies will cover situations like neutropenia, low-level CMV, the importance of CD4 T Cells and more. Learn when they use CMV inSIGHT T Cell Immunity testing to evaluate CMV-specific cell mediated immunity, what they do with the information from the lab report, and the outcomes of their patients. Including a recording of the Live Q&A at the end of the original presentation.

Peanut allergy is one of the most common food allergies, affecting approximately 1% of the US population [1], and the prevalence of peanut allergy is thought to be increasing [2]. In allergic individuals, anaphylaxis following exposure to peanuts can be fatal, requiring these individuals to carry epinephrine injectors at all times. Perhaps due to the serious nature of peanut allergies and its wide recognition, as many as 3 in 4 individuals are misdiagnosed as having peanut allergies [3], when in fact they have either asymptomatic to mild peanut sensitization or no sensitization at all.

BK Polyomavirus and thrombotic microangiopathy (TMA) are significant complications following stem cell transplantation, leading to serious health risks. In this presentation, Dr. Ben Laskin, Dr. Sonata Jodele, and Dr. Steve Kleiboeker discuss the current understanding of these conditions and highlight gaps in knowledge and treatment strategies. While advances have been made in diagnosing and managing BK virus-related complications, unmet needs remain in effectively addressing TMA. The presentation underscores the importance of continued research and collaboration to improve patient outcomes.

Accurate and early identification of patients at high-risk for severe acute graft versus host disease (aGVHD) and related complications has the potential to improve patient outcomes following allogeneic hematopoietic cell transplantation (alloHCT). High-risk patients can be preemptively treated for aGVHD prior to the onset of clinical disease while low-risk patients may potentially avoid unnecessary treatment. Validation of an interpretive algorithm based on serum ST2 and REG3α levels accurately predicts risks for allo-HCT patients when testing is performed at 7 days post-transplant, at the onset of aGVHD symptoms, and ≥ 1 week after the initiation of systemic therapy.